Copyright
©The Author(s) 2019.
World J Clin Oncol. Feb 24, 2019; 10(2): 75-85
Published online Feb 24, 2019. doi: 10.5306/wjco.v10.i2.75
Published online Feb 24, 2019. doi: 10.5306/wjco.v10.i2.75
Figure 1 Survival curves for progression free survival and overall survival.
A, B: Kaplan-Meier estimates for progression-free survival (A) and overall survival (B); C, D: Kaplan-Meier estimates for progression-free survival (C) and overall survival (D); patients were stratified according to their treatment: FOLFIRI3 (in red), FOLFIRI3 plus bevacizumab (in blue) or FOLFIRI3 plus aflibercept (in yellow). aP-value < 0.05.
- Citation: Devaux M, Gerard L, Richard C, Bengrine-Lefevre L, Vincent J, Schmitt A, Ghiringhelli F. Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. World J Clin Oncol 2019; 10(2): 75-85
- URL: https://www.wjgnet.com/2218-4333/full/v10/i2/75.htm
- DOI: https://dx.doi.org/10.5306/wjco.v10.i2.75